CJC-1295 Without DAC / MOD GRF 1–29
The best known human pharmacology study assessed DAC CJC-1295 in healthy adults.
View record and quotation
10 research recordsEarly human Late stage Authorised product Preclinical Preclinical Early human Early human Preclinical Early human Authorised product
Growth Hormone & Endocrine Research
Explore growth hormone releasing peptides and endocrine research tools, including Sermorelin, Tesamorelin and CJC-1295 variants. Each record distinguishes the named material from related analogues.
Research materials only. Not for human or animal consumption.
Sermorelin
Research concerns GH stimulation testing and historical pediatric growth failure treatment.
View record and quotationTesamorelin
A GHRH analogue with randomised evidence of reduced visceral abdominal fat in adults with HIV associated lipodystrophy; defined finished products are authorised for that specific context, not general weight loss.
View record and quotationAmunine
Direct evidence is older endocrine physiology and biochemical purification work, including 1982 pituitary cell and dog studies.
Read research recordGHRP-2
Human research has largely examined acute endocrine pharmacology, GH stimulation/testing, pharmacokinetics, and appetite biology.
Read research recordGHRP-6
Research is mainly experimental endocrine pharmacology, receptor biology, pharmacokinetics, and preclinical tissue protection work.
Read research recordHexarelin
Research predominantly examines short term GH and pituitary responses.
Read research recordHGH Fragment 177–191
Evidence is largely rodent, isolated adipose tissue, and mechanistic research concerning lipid metabolism.
Read research recordIpamorelin
Research includes pituitary cell, rat, and swine pharmacology and a registered human postoperative gastrointestinal function study.
Read research recordTetracosactide Acetate
Its established context is regulated adrenal reserve diagnostic stimulation.
Read research record